A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using PET Imaging

What is the purpose of this trial?

This study is investigational and is being done to find out if it is possible to use early periodic PET scans to identify those patients who are not responding to a combination of standard chemotherapy called "ABVD" (the drugs doxorubicin, bleomycin, vinblastine and dacarbazine). This approach would allow an earlier switch to a more intensive combination chemotherapy called "BEACOPP" (the drugs bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone). We would like to find out if the experimental treatment of switching from ABVD to BEACOPP using periodic PET scanning will improve the chances that your Hodgkin lymphoma will be cured. We also want to compare what kind of side effects this experimental treatment can cause and how often they occur.

---

Participation Guidelines

Click here for detailed information about who can participate in this trial.

---

Sponsor:

Southwest Oncology Group

Dates:

June 2012

Last Updated:

Study HIC#:

1101007919

Clinicaltrials.gov ID: Yale7881847